@article{0ef7afb59c194077bffb27387dc18d63,
title = "Introduction to the National Cancer Imaging Translational Accelerator (NCITA): a UK-wide infrastructure for multicentre clinical translation of cancer imaging biomarkers",
abstract = "The National Cancer Imaging Translational Accelerator (NCITA) is creating a UK national coordinated infrastructure for accelerated translation of imaging biomarkers for clinical use. Through the development of standardised protocols, data integration tools and ongoing training programmes, NCITA provides a unique scalable infrastructure for imaging biomarker qualification using multicentre clinical studies.",
author = "McAteer, \{M. A.\} and O{\textquoteright}Connor, \{J. P.B.\} and Koh, \{D. M.\} and Leung, \{H. Y.\} and Doran, \{S. J.\} and M. Jauregui-Osoro and N. Muirhead and C. Brew-Graves and Plummer, \{E. R.\} and E. Sala and T. Ng and Aboagye, \{E. O.\} and Higgins, \{G. S.\} and S. Punwani",
note = "Funding Information: The National Cancer Imaging Translational Accelerator (NCITA) is a clinical imaging research consortium, which is creating the necessary integrated infrastructure to accelerate robust qualification of cancer imaging biomarkers for clinical use, as proposed in the Imaging Biomarker Roadmap for Cancer Studies [5]. Established in 2019, through Cancer Research UK (CRUK) Accelerator award funding, NCITA builds on previous Cancer Imaging Centres Initiatives (2008–2018), funded by CRUK and the Engineering and Physical Sciences Research Council (EPSRC), which were pivotal in driving innovation in biomarker research using novel imaging techniques [6–11]. NCITA brings together nine UK centres of excellence for medical imaging, namely, University College London, The University of Manchester, University of Oxford, King{\textquoteright}s College London, The Institute of Cancer Research (ICR), Imperial College London, University of Cambridge, University of Glasgow and Newcastle University (Supplementary 1). This multi-institutional collaborative network includes medical imaging experts, clinical oncologists, physicists and research scientists who are developing standardised imaging biomarker qualification pipelines to accelerate the development of qualified imaging biomarkers using multicentre studies. Funding Information: NCITA is funded by a Cancer Research UK Accelerator Award (C42780/A27066 (University College London; PI Professor Shonit Punwani); C34326/A28684 (University of Oxford; PI Professor Geoff Higgins); C1922/A28683 (University of Manchester; PI Professor James O{\textquoteright}Connor); C22479/A28667 (University of Cambridge; PI Professor Evis Sala); C2536/A28680 (Imperial College London; PI Professor Eric Aboagye); C7273/ A28677 (Institute of Cancer Research, London; PI Professor Dow Mu Koh); C1519/A28682 (King{\textquoteright}s College London; PI Professor Tony Ng). The Panorama Trial (NCITA Exemplar study) received support from the Cancer Research UK KCL-UCL Comprehensive Cancer Imaging Centre (C1519/A16463 (2013-18) C1519/A10331 (2008-13)). Publisher Copyright: {\textcopyright} 2021, The Author(s). Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = nov,
day = "23",
doi = "10.1038/s41416-021-01497-5",
language = "English",
volume = "125",
pages = "1462--1465",
journal = "British journal of cancer",
issn = "0007-0920",
publisher = "Springer Nature [academic journals on nature.com]",
number = "11",
}
SDG 3 Good Health and Well-being